2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sittenMonday teaser v2: The two-stage rocket, circVec 4.0 which has not been tested in the central nervous system before, and the bystander effect can lead to a strong repricing. In gene therapy, viruses (AAV) act as messengers to deliver the recipe for a gene. When Circio packages circVec into the virus, the package is called circVec-AAV. Since brain tissue is extremely dense, the virus often only reaches a few percent of the cells. For secreted proteins, circVec 4.0 ensures such a massive overproduction that the excess is secreted into the brain tissue. Thus, the sick neighboring cells, which the virus never hit, pick up the medicine from the outside and are saved nonetheless (via the bystander effect). This removes the need for massive, harmful virus doses to reach every single cell; it is enough to hit a few that pump out 20 to 50x more protein over time. In Q3, Circio will present protein quantity per virus particle in vivo with a standard test gene to validate platform performance. In Q4, we will get the results from the BP partner with the same setup, but with their own drug. Yes, of course, a complex drug requires more from the cell than a test gene. But the point is that strong Q3 data in practice refutes the platform risk and enormously removes risk from the Q4 reading before the partner data is even available. And a little bonus hint at the end: Note that Circio has just brought Dr. Dinah Sah onto the board. She is a former Chief Scientific Officer (CSO) at Voyager Therapeutics, where she worked with exactly this: AAV gene therapy against neurological diseases. My hypothesis is that such skilled people at this level will not join a board unless they have seen that the technology actually delivers. Have a good rest of the stock market week :)
·8 t sittenTimewise, one is now entering the last 2 weeks of August month and announcements normally come then in connection with H1 update. In 2025, the presentation was on 28. August a Thursday and notice of this was sent out 21. August. This is what the stock exchange announcement 28. Aug. 2025 looked like: https://www.circio.com/en/circio-presents-new-circvec-aav-vectors-showing-up-to-40x-enhanced-activity-in-first-half-year-report-webcast/ As one sees, a significant R&D update which also should be expected this year.In August 2025 it wasn't like that, but now with good news one can, for example, get an increase to 12, and then the underlying values, which one can probably say have risen from approx 7 kr today (9 minus 2 cash) to 10 kr. So yes, it can be well-founded FOMO going forward. Personally, I believe these 7 kr can quickly double in a relatively short time, among other things, there has still not been a significant entry of larger investors, even though there is some trading via USA banks.
·8 t sitten · Muokattu"Little" Circio, which when many of us bought the share was around 50 øre, in 9th place among most traded shares at Nordnet last week. With just net sales. Not so surprising that there was slightly more selling than buying, that's how it is in a period without big news but with a relatively good increase over time. Good interest in the share is positive! Then it's good to remind that yes: this share will probably continue to fluctuate a good deal. Finally: A lot of irrelevant rubbish on this forum. Don't act like an idiot. It's actually not big news that the share goes down a few percent and one doesn't need to babble like an unstable teenager for that reason. Have a nice week!
·11 t sittenAs expected, it was red on Friday. No news is bad news here, and then many become skeptical. That's just how it is. I have said it will remain in this area for some time ahead. Hold onto your coffee cup and follow along.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenMonday teaser v2: The two-stage rocket, circVec 4.0 which has not been tested in the central nervous system before, and the bystander effect can lead to a strong repricing. In gene therapy, viruses (AAV) act as messengers to deliver the recipe for a gene. When Circio packages circVec into the virus, the package is called circVec-AAV. Since brain tissue is extremely dense, the virus often only reaches a few percent of the cells. For secreted proteins, circVec 4.0 ensures such a massive overproduction that the excess is secreted into the brain tissue. Thus, the sick neighboring cells, which the virus never hit, pick up the medicine from the outside and are saved nonetheless (via the bystander effect). This removes the need for massive, harmful virus doses to reach every single cell; it is enough to hit a few that pump out 20 to 50x more protein over time. In Q3, Circio will present protein quantity per virus particle in vivo with a standard test gene to validate platform performance. In Q4, we will get the results from the BP partner with the same setup, but with their own drug. Yes, of course, a complex drug requires more from the cell than a test gene. But the point is that strong Q3 data in practice refutes the platform risk and enormously removes risk from the Q4 reading before the partner data is even available. And a little bonus hint at the end: Note that Circio has just brought Dr. Dinah Sah onto the board. She is a former Chief Scientific Officer (CSO) at Voyager Therapeutics, where she worked with exactly this: AAV gene therapy against neurological diseases. My hypothesis is that such skilled people at this level will not join a board unless they have seen that the technology actually delivers. Have a good rest of the stock market week :)
- ·8 t sittenTimewise, one is now entering the last 2 weeks of August month and announcements normally come then in connection with H1 update. In 2025, the presentation was on 28. August a Thursday and notice of this was sent out 21. August. This is what the stock exchange announcement 28. Aug. 2025 looked like: https://www.circio.com/en/circio-presents-new-circvec-aav-vectors-showing-up-to-40x-enhanced-activity-in-first-half-year-report-webcast/ As one sees, a significant R&D update which also should be expected this year.In August 2025 it wasn't like that, but now with good news one can, for example, get an increase to 12, and then the underlying values, which one can probably say have risen from approx 7 kr today (9 minus 2 cash) to 10 kr. So yes, it can be well-founded FOMO going forward. Personally, I believe these 7 kr can quickly double in a relatively short time, among other things, there has still not been a significant entry of larger investors, even though there is some trading via USA banks.
- ·8 t sitten · Muokattu"Little" Circio, which when many of us bought the share was around 50 øre, in 9th place among most traded shares at Nordnet last week. With just net sales. Not so surprising that there was slightly more selling than buying, that's how it is in a period without big news but with a relatively good increase over time. Good interest in the share is positive! Then it's good to remind that yes: this share will probably continue to fluctuate a good deal. Finally: A lot of irrelevant rubbish on this forum. Don't act like an idiot. It's actually not big news that the share goes down a few percent and one doesn't need to babble like an unstable teenager for that reason. Have a nice week!
- ·11 t sittenAs expected, it was red on Friday. No news is bad news here, and then many become skeptical. That's just how it is. I have said it will remain in this area for some time ahead. Hold onto your coffee cup and follow along.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenMonday teaser v2: The two-stage rocket, circVec 4.0 which has not been tested in the central nervous system before, and the bystander effect can lead to a strong repricing. In gene therapy, viruses (AAV) act as messengers to deliver the recipe for a gene. When Circio packages circVec into the virus, the package is called circVec-AAV. Since brain tissue is extremely dense, the virus often only reaches a few percent of the cells. For secreted proteins, circVec 4.0 ensures such a massive overproduction that the excess is secreted into the brain tissue. Thus, the sick neighboring cells, which the virus never hit, pick up the medicine from the outside and are saved nonetheless (via the bystander effect). This removes the need for massive, harmful virus doses to reach every single cell; it is enough to hit a few that pump out 20 to 50x more protein over time. In Q3, Circio will present protein quantity per virus particle in vivo with a standard test gene to validate platform performance. In Q4, we will get the results from the BP partner with the same setup, but with their own drug. Yes, of course, a complex drug requires more from the cell than a test gene. But the point is that strong Q3 data in practice refutes the platform risk and enormously removes risk from the Q4 reading before the partner data is even available. And a little bonus hint at the end: Note that Circio has just brought Dr. Dinah Sah onto the board. She is a former Chief Scientific Officer (CSO) at Voyager Therapeutics, where she worked with exactly this: AAV gene therapy against neurological diseases. My hypothesis is that such skilled people at this level will not join a board unless they have seen that the technology actually delivers. Have a good rest of the stock market week :)
- ·8 t sittenTimewise, one is now entering the last 2 weeks of August month and announcements normally come then in connection with H1 update. In 2025, the presentation was on 28. August a Thursday and notice of this was sent out 21. August. This is what the stock exchange announcement 28. Aug. 2025 looked like: https://www.circio.com/en/circio-presents-new-circvec-aav-vectors-showing-up-to-40x-enhanced-activity-in-first-half-year-report-webcast/ As one sees, a significant R&D update which also should be expected this year.In August 2025 it wasn't like that, but now with good news one can, for example, get an increase to 12, and then the underlying values, which one can probably say have risen from approx 7 kr today (9 minus 2 cash) to 10 kr. So yes, it can be well-founded FOMO going forward. Personally, I believe these 7 kr can quickly double in a relatively short time, among other things, there has still not been a significant entry of larger investors, even though there is some trading via USA banks.
- ·8 t sitten · Muokattu"Little" Circio, which when many of us bought the share was around 50 øre, in 9th place among most traded shares at Nordnet last week. With just net sales. Not so surprising that there was slightly more selling than buying, that's how it is in a period without big news but with a relatively good increase over time. Good interest in the share is positive! Then it's good to remind that yes: this share will probably continue to fluctuate a good deal. Finally: A lot of irrelevant rubbish on this forum. Don't act like an idiot. It's actually not big news that the share goes down a few percent and one doesn't need to babble like an unstable teenager for that reason. Have a nice week!
- ·11 t sittenAs expected, it was red on Friday. No news is bad news here, and then many become skeptical. That's just how it is. I have said it will remain in this area for some time ahead. Hold onto your coffee cup and follow along.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt